AVEO Pharmaceuticals, Inc. (AVEO)

[Biotech Pharmer]

Tivozanib significantly improves PFS and ORR compared to sorafenib in patients with treatment-refractory advanced RCC. Tivozanib was superior in patients previously treated with checkpoint inhibitors as well as two VEGFR-TKIs. Responses with tivozanib were more durable than sorafenib. Tivozanib was well tolerated with hypertension as the most common adverse event. Lower rates of hand foot syndrome, diarrhea, and rash were observed for tivozanib compared to sorafenib. OS data are immature with final analysis pending. It's clear that Q4 is worth waiting for.